STROKE - A POSSIBLE ADVERSE EFFECT OF COMBINATION THERAPY WITH PARITAPREVIR/RITONAVIR/OMBITASVIR + DASABUVIR. CASE REPORT

The development of direct-acting antiviral agents against hepatitis C virus has revolutionized the management and control of this important liver disease. Combination therapy with paritaprevir/ritonavir/ombitasvir + dasabuvir is considered one of the most effective and well-tolerated regimens used to treat chronic hepatitis C, with response rates over 95%. Ease of administration, excellent tolerance, and the absence of severe side effects have made treatment of chronic hepatitis C possible even in patients with severe fibrosis and in those with comorbidities. Insomnia, headache and fatigue are the most commonly reported side effects, the serious adverse events being uncommon. We will report a case of stroke as a possible serious adverse effect during treatment with paritaprevir/ritonavir/ombitasvir + dasabuvir (PrOD) in a 61-year-old male, former smoker, without cardiovascular history, in whom a conflict situation resulted in a hypertensive episode accompanied by paresthesia in the upper and lower right limbs, vertigo, equilibrium disorder, which turned out to be a stroke. Conclusions: Because the reported case may be a rare serious effect during the treatment with parita previr/ritonavir/ombitasvir + dasabuvir in a patient with hepatitis C virus (HCV) cirrhosis and without a cardiovascular history, careful neurological monitoring is recommended during this therapeutic regimen.